Related Experiment Video

Updated: May 1, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Reply to "triple or dual therapy for HCV-1 naive patients? Optimizing selection tools"

Orazio Palmieri1, Maria Rosa Valvano1, Maurizio Margaglione2

  • 1Division of Gastroenterology, "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo, Italy.

Journal of Hepatology
|March 29, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

11.2K

Related Experiment Videos

Last Updated: May 1, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

11.2K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

43.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Hepatitis01:25

Hepatitis

86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86

Articles linked to this work by shared authors, journal, and citation graph.

Sex-Related Differences and Predictors of Mortality in Patients Undergoing Major Orthopaedic Surgery: Insights from the ORTHO-START Registry.

Seminars in thrombosis and hemostasis·2026

Geographical and Ethnic Heterogeneity in Genetic Dilated Cardiomyopathies.

International journal of molecular sciences·2026

Unmasking Brugada ECG Pattern in Myotonic Dystrophy Type 2 With an ANK2 Variant.

Pacing and clinical electrophysiology : PACE·2026

Identifying Thromboprophylaxis and Aspirin Use in Pregnancy: Predictors and Maternal Outcomes-the Italian MoMs Study.

Thrombosis and haemostasis·2025

Pathophysiology of Pulmonary Arterial Hypertension: Focus on Vascular Endothelium as a Potential Therapeutic Target.

International journal of molecular sciences·2025

Clinical and Genetic Heterogeneity of Factor XI Deficiency: Insights from a Southern Italian Cohort.

International journal of molecular sciences·2025

The future of blood-based biomarkers in liver cancer.

Journal of hepatology·2026

Corticosteroid Therapy for Drug-induced Liver Injury: Mind the Gap!

Journal of hepatology·2026

Systemic therapy of biliary tract cancer: The road to personalised strategies.

Journal of hepatology·2026

Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests.

Journal of hepatology·2026

The changing epidemiology of primary liver cancer in the 21st century.

Journal of hepatology·2026

Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction.

Journal of hepatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us